Barinthus Biotherapeutics Reports $5.5 Million Net Loss in Q1 2026, Sees Significant Expense Reductions

Barinthus Biotherapeutics plc reported a net loss of $5.5 million for the first quarter of 2026, a significant improvement compared to a net loss of $19.7 million during the same period in 2025. The company's total operating expenses decreased to $6.1 million from $20.9 million year-over-year, primarily due to reduced research and development costs, which fell to $3.6 million from $8.3 million. General and administrative expenses also saw a decline, dropping from $12.6 million to $2.5 million, largely attributed to a foreign exchange gain of $3.0 million compared to a loss of $4.4 million in the prior year.

The company’s cash, cash equivalents, and restricted cash totaled $67.2 million as of March 31, 2026, down from $71.9 million at the end of 2025. This decrease was primarily due to cash used in operating activities, which amounted to $3.4 million for the quarter. Barinthus reported an accumulated deficit of $309.6 million as of the end of the first quarter, reflecting ongoing investments in its clinical development programs. The company anticipates continued operating losses as it advances its product candidates through clinical trials and seeks regulatory approvals.

Strategically, Barinthus is focused on its proprietary SNAP-TI platform for developing immunotherapeutic drug candidates targeting autoimmune and inflammatory diseases. The company is currently assessing its lead candidate, VTP-1000, in a Phase 1 clinical trial aimed at treating celiac disease. Additionally, Barinthus is in the process of merging with Clywedog Therapeutics, a transaction expected to close in mid-2026, which will enhance its portfolio of clinical-stage candidates. The merger agreement was amended in February 2026 to provide additional flexibility in finalizing terms.

Operationally, Barinthus has streamlined its research and development efforts, resulting in a reduction of personnel-related expenses and a shift in focus away from infectious disease and oncology programs. The company has also incorporated two new subsidiaries to facilitate the merger with Clywedog. As of March 31, 2026, Barinthus had 40,848,893 ordinary shares outstanding, with no new shares issued during the quarter. The company continues to explore partnerships to fund its ongoing clinical programs, particularly for VTP-300, which targets chronic hepatitis B.

Looking ahead, Barinthus expects to incur additional losses as it continues to invest in its clinical development pipeline. The company is actively seeking additional funding sources to support its operations and has indicated that its existing cash reserves should be sufficient to cover operational expenses for at least the next 12 months. However, the company acknowledges the inherent risks in drug development and the uncertainty surrounding future revenue generation from its product candidates.